Novo Nordisk A/S (NVO): Price and Financial Metrics


Novo Nordisk A/S (NVO)

Today's Latest Price: $64.96 USD

2.17 (3.46%)

Updated May 28 6:40pm

Add NVO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVO Stock Summary

  • NVO has a higher market value than 99.15% of US stocks; more precisely, its current market capitalization is $153,169,184,000.
  • With a one year PEG ratio of 738.75, Novo Nordisk A S is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.47% of US stocks.
  • With a year-over-year growth in debt of 747.44%, Novo Nordisk A S's debt growth rate surpasses 97.44% of about US stocks.
  • Stocks that are quantitatively similar to NVO, based on their financial statements, market capitalization, and price volatility, are ABT, AZN, SAP, TMO, and MDT.
  • Visit NVO's SEC page to see the company's official filings. To visit the company's web site, go to www.novonordisk.com.
NVO Daily Price Range
NVO 52-Week Price Range

NVO Stock Price Chart More Charts


NVO Price/Volume Stats

Current price $64.96 52-week high $66.02
Prev. close $62.79 52-week low $46.85
Day low $64.13 Volume 1,617,200
Day high $65.56 Avg. volume 1,958,440
50-day MA $60.99 Dividend yield 1.72%
200-day MA $57.50 Market Cap 152.97B

Novo Nordisk A/S (NVO) Company Bio


Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.

NVO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$64.96$157.69151%

We started the process of determining a valid price forecast for Novo Nordisk A S with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novo Nordisk A S ranked in the 68th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 152.5%. As for the metrics that stood out in our discounted cash flow analysis of Novo Nordisk A S, consider:

  • The company has produced more trailing twelve month cash flow than 99.55% of its sector Healthcare.
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 3.68% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 62.87% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%146%
1%149%
2%151%
3%154%
4%156%
5%159%

FMS, DVA, JAZZ, QDEL, and AMPH can be thought of as valuation peers to NVO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


NVO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NVO Latest Social Stream


Loading social stream, please wait...

View Full NVO Social Stream

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Insulin Market Report 2020: Includes Revenue Data (2013-2022) for Novo Nordisk, Sanofi Aventis, Eli Lilly, Merck & Co, and Beckton Dickinson

DUBLIN, May 27, 2020 /PRNewswire/ -- The "Global Insulin Market - Focus on Insulin Delivery Devices [By Devices - Vials & Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors; By Region - North America (The US), Europe (The UK, Germany, France & Italy) and Asia Pacific (Japan,…

PR Newswire | May 27, 2020

Novo Nordisk leased the 9th floor in Tiriac Tower office building

CBRE, leader in the real estate consultancy market, advised the relocation process for the pharmaceutical company Novo Nordisk, who leased an area of 580 sq m offices in the Tiriac Tower building, located in Victoriei Square. The transaction was signed in March, in full swing of the COVID-19 pandemic lockdown, thus confirming the continuity of […] The post Novo Nordisk leased the 9th floor in Tiriac Tower office building appeared first on Business Review .

Business Review | May 26, 2020

Outlook on the Global Diabetes Disposable Insulin Delivery Pen Industry to 2026 - Major Players Analysed are Novo Nordisk, Eli Lilly & Sanofi Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Worldwide Diabetes Disposable Insulin Delivery Pen Market Prospect, Share, Development, Growth & Demand Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Worldwide Diabetes Disposable Insulin Delivery Pen Market size is anticipated to exceed USD 14 billion by 2026. The objective of this market research report is to provide a comprehensive analysis of the fast-evolving, high-growth worldwide diabetes disposable insulin delivery pe

Business Wire | May 22, 2020

'No team changes lives like our team.' How cycling's Team Novo Nordisk turned type 1 diabetes into its 'greatest strength'

Team Novo Nordisk, a professional cycling team made up of riders with type 1 diabetes, harbors a dream of competing at the Tour de France, the holy grail of road cycling.

CNN RSS | May 19, 2020

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

Zacks Investment Research | May 8, 2020

Read More 'NVO' Stories Here

NVO Price Returns

1-mo 3.05%
3-mo 12.87%
6-mo 16.84%
1-year 39.94%
3-year 63.38%
5-year 25.45%
YTD 13.35%
2019 27.79%
2018 -12.54%
2017 52.92%
2016 -37.03%
2015 39.39%

NVO Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full NVO Dividend History

Continue Researching NVO

Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:

Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8926 seconds.